Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
Umamon Puangthong, Ging-Yuek Robin HsiungDivision of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, CanadaAbstract: Alzheimer’s disease is the most common cause of dementia in older adults. The clinical features include progressive memory decline as w...
Guardado en:
Autores principales: | Umamon Puangthong, Ging-Yuek Robin Hsiung |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1c0efbf441974682b0e6a854784148e5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Update on the use of memantine in Alzheimer’s disease
por: Robert J van Marum
Publicado: (2009) -
Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands
por: Hoogveldt B, et al.
Publicado: (2011) -
Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi T, et al.
Publicado: (2018) -
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
por: Kano O, et al.
Publicado: (2013) -
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
por: Stuart J Thomas, et al.
Publicado: (2009)